MMSI14, a 14 Gene Model for Risk Assessment in Multiple Myeloma

University Reference Number: U-5098
Web Published: Jul 30, 2012

Invention Summary

Risk assessment in multiple myeloma is important to direct clinical treatments.  Investigators at the University of Utah have developed a new gene model, the MM Survival Index14 (MMSI14) for classification of multiple myeloma. The MMSI14 is the first gene expression signature focused on both low-risk and high-risk disease.  An initial study using multivariate comparative analysis confirms that MMSI14 is the best available model to predict clinical outcome in MM patients. 


Features and Benefits


  • The MMSI14 is the only gene expression signature to give actionable information on both low and high risk disease in multiple myeloma.

  • The MMSI14 appears to have superior prognostic power compared to gene signatures currently being applied for classification of multiple myeloma. 

  • Clinical application of the MMSI14 will provide information needed to design the optimal therapy for patients, enabling truly personalized treatment.


Market Opportunity

Multiple myeloma is the second most common hematological malignancy in the United States.  Despite remarkable improvements in the treatment over the past decade, clinical management of this disease remains challenging. Defining both low-risk and high-risk disease is crucial for determining optimal therapies for specific risk groups.


Intellectual Property:  An international/PCT patent application is pending.



Related Publications:  Chen et al , "Low-risk identification in multiple myeloma using a new 14-gene model" Eur J. Haemotol. 2012, 90:28-36.



Patent Information:
Licensing Contact:
Beth Drees
Director of Business & Technology Development
University of Utah
Fenghuang (Frank) Zhan
Tiehua Chen
Guido Tricot
Maurizio Zangari